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Guest Editorial
Cardiovascular Disease Prevention: What Makes an Intervention
Worthwhile?
CYRUS R KUMANA and BERNARD M Y CHEUNG
From Department of Medicine, The University of Hong Kong and Queen Mary Hospital, Hong Kong

In the context of medical practice, it is always
pertinent to consider what makes a given intervention
worthwhile? The misconceptions on which such
decisions were based, the ironic and sometimes ethical
dilemmas which ensued and the challenges they still
pose are amply demonstrated by the profession's
struggle to formulate guidelines for the prevention of
cardiovascular diseases. Whilst accepting that such
decisions must ultimately depend on the prevailing
circumstances (individual socioeconomic priorities), in
the past such recommendations were largely concerned
with modifying a composite of correctable individual
risk factors, based on what was known about the relative
risk reduction (RRR) likely to be achieved. These risk
factors included smoking, sedentary life style,
hypertension, hypercholesterolaemia and obesity.
Moreover, recommendations were commonly based on
equating the clinical significance of modifying
corresponding surrogate markers whatever the means
(or drug).
The latter assumptions notwithstanding,
recognising and understanding the importance of
absolute risk reduction (ARR) over a given period of
time, and its reciprocal, the number needed to treat
(NNT), has been a major new advance. Since these two
interdependent parameters convey a much fairer idea
as to how worthwhile a given intervention might be in
relation to others, they are also an aid to setting
priorities. Deciding whether to consider an intervention
as worthwhile under any given set of circumstances then
becomes somewhat easier.
This point is abundantly illustrated when
comparing RRRs and NNTs to describe coronary heart
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disease (CHD) event prevention following long-term
intervention with statins under different circumstances
in similarly aged adults.1 Thus, in four large-scale,
randomised, placebo-controlled clinical trials of
outcome, groups receiving statins all experienced the
same magnitude of plasma cholesterol lowering and
RRR for prevention of CHD events (24-37%). On the
contrary, NNT was a highly discriminating parameter.
Thus, in the 4S trial 2 involving patients with both
coronary artery disease and hypercholesterolaemia,
patients receiving active treatment enjoyed an
NNT/year of 63 as opposed to 256 in persons with
neither among participants of the AFCAPS/TexCAPS
trial.3 In the remaining trials, among persons who all
had CHD only (CARE)4 or hypercholesterolaemia only
(WOSCOP),5 values for NNT/year were intermediate.
Clearly, relative to persons with neither risk factor, those
with both required that about four times fewer persons
needed to receive statin just to prevent a single
individual experiencing a CHD event. In other words,
a much smaller effort had to be expended in persons at
higher risk. Recourse to NNTs (but not RRRs) for
different cardiovascular events, also illustrated that
statins have a much more marked effect on preventing
CHD than strokes; respective values for stroke
prevention consistently being much greater than for
CHD event prevention. Furthermore, in the same four
trials calculation of the NNTs (± 95% CIs) to prevent
death from any cause reveal that a reduction in overall
mortality can only be inferred with confidence, among
patients with both CHD and hypercholesterolaemia.
NNTs also indicate how many individuals must
necessarily incur the expense, inconvenience and risk
of adverse effects from such drug treatment over a given
period of time, just to save one person from experiencing
the defined event.
Consideration of ARR has also been one of the
key innovations in the new British Hypertension Society
Guidelines for the management of hypertension.6,7 One
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of its recommendations is a formal estimation of a
subject's 10 year CHD risk in order to decide whether
or not to treat a patient with mild hypertension. In this
context recourse to ARR rather than RRR is certainly a
laudable development, as it provides direct information
about likely real benefits over time. Regrettably
however, this approach does not take age into account.
As elderly patients have inherently higher risks
of disease and death, treatment decisions based on risk
alone will always favour the elderly. In other words, an
elderly person with very mild hypertension or very mild
hyperlipidaemia readily attains the 1.5% or so annual
risk of events that mandates treatment. Whereas a young
person, even with multiple risk factors, may not reach
the same level of annual risk. If treatment decisions are
to be based solely on risk, then implementing this
strategy will lead to therapeutic decisions that run
contrary to common sense. The problem is that knowing
the baseline risk, (i.e. the risk of no treatment), is not
enough. One also needs to know the benefits of
treatment. In this regard, the benefit is directly related
to the life expectancy. A cardiovascular death at 50
represents, say 20 years of life lost, whereas a death at
75 could represent only 5 lost years.
In the absence of a full assessment of risk and
benefit (quality life years preserved), basing treatment
decisions on the 10 year cardiovascular risk alone is
inadequate and may lead to inappropriate and
inequitable allocation of resources. There is a real
danger that this policy will tend to conserve the most
aged members of the population by prolonging life in
the extremely elderly, whilst forgoing the prevention
of premature deaths through withholding treatment in
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the young. The solution is to use the NNT to gain one
year of life (or better still one quality adjusted life year
or QALY), to evaluate the effectiveness of an
intervention. This will take into account differential
potential benefits accruing from the intervention in
terms of remaining life expectancy (or QALYS) in the
young as opposed to the elderly.
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